发明名称 Bicyclic sulfonamide compounds as sodium channel inhibitors
摘要 The present invention provides compounds of Formula I,; and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
申请公布号 US9458152(B2) 申请公布日期 2016.10.04
申请号 US201514920833 申请日期 2015.10.22
申请人 Amgen Inc. 发明人 Weiss Matthew;Boezio Alessandro;Boezio Christiane;Butler John R.;Chu-Moyer Margaret Yuhua;Dimauro Erin F.;Dineen Thomas;Graceffa Russell;Guzman-Perez Angel;Huang Hongbing;Kreiman Charles;La Daniel;Marx Isaac E.;Milgram Benjamin Charles;Nguyen Hanh Nho;Peterson Emily Anne;Vaida Karina R.;Sparling Brian
分类号 A61K31/00;C07D417/14;C07D471/04;C07D413/12;C07D401/12;C07D413/14;C07D417/12;C07C53/18;C07D215/227;C07D403/12;C07D215/36;C07D241/44;C07D401/14 主分类号 A61K31/00
代理机构 代理人 Lemoine Elsa D.
主权项 1. A compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: wherein each Ra is independently H, halo, —OH, —NRbRb, —C1-6alkyl, —OC1-6alkyl, —C1-6haloalkyl, —OC1-6haloalkyl or —CN, and R1 is a 5 to 10 membered aryl or heteroaryl, wherein the heteroaryl group can have from 1 to 3 heteroatoms independently selected from O, N or S, and the aryl or heteroaryl group can be unsubstituted or substituted with from 1 to 4 substituents independently selected from halo, —NRbRb, —C1-6alkyl, —OC1-6alkyl, —OC1-6alkylCF3, —OC1-6alkylCN, —C1-6alkylOC1-6alkyl, —(SO2)C1-6alkyl, —(SO2)NRbRb, hydroxyC1-6alkyl, —CF3, —CHF2, —CH2F, —OCF3, —OCHF2, —OCH2F, —(CReRe)mCN, —C(═O)NRbRb, —C(═O)ORb, —N(CReRe)mA, —N(Re)(CReRe)mA, —(C═N)OC1-6alkyl, —(C═O)N(Re)(CReRe)mA, (C═O)N(Re)(CReRe)mCF3, —O(CReRe)mA, —O(CReRe)mOA or —C(═O)A; A is a 4 to 9 membered aryl, heteroaryl or heterocycloalkyl group, where the heteroaryl or heterocycloalkyl group can have from 1 to 3 heteroatoms independently selected from O, N or S, or a 3 to 6 membered cycloalkyl group, and the aryl, heteroaryl, heterocycloalkyl or cycloalkyl group can be unsubstituted or substituted with from 1 to 4 substituents independently selected from halo, —NRbRb, —C1-6alkyl, —OC1-6alkyl, —(CReRe)mOH, hydroxyC1-6alkyl, —CF3, —CHF2, —CH2F, —OCF3, —OCHF2, —OCH2F, —CN, —C(═O)NRbRb, —O(CReRe)mB or —(CReRe)mB; B is a 5 to 6 membered aryl, heteroaryl or heterocycloalkyl group, where the heteroaryl or heterocycloalkyl group can have from 1 to 3 heteroatoms independently selected from O, N or S, or a 3 to 5 membered cycloalkyl group, and the aryl, heteroaryl, cycloalkyl or heterocycloalkyl group can be unsubstituted or substituted with from 1 to 4 substituents independently selected from halo, —NRbRb, —C1-6alkyl, —OC1-6alkyl, hydroxyC1-6alkyl, —CF3, —CHF2, —CH2F, —OCF3, —OCHF2, —OCH2F, —CN or —C(═O)NRbRb; R2 is a 5 to 10 membered aryl or heteroaryl, where the heteroaryl group can have from 1 to 3 heteroatoms independently selected from O, N or S, and the aryl or heteroaryl group can be unsubstituted or substituted with from 1 to 4 substituents independently selected from halo, —NRbRb, —C1-6alkyl, —OC1-6alkyl, hydroxyC1-6alkyl, —(CRcRc)nNRbRb, —CF3, —CHF2, —CH2F, —OCF3, —OCHF2, —OCH2F, —CN or —C(═O)NRbRb; each Rb is independently H or —C1-6alkyl; each Rc is independently H or —C1-6alkyl; and each Rd is independently H, halo, —CN, —NRcRc, —OH, —C1-6alkyl, —C1-6haloalkyl, —OC1-6haloalkyl or —OC1-6alkyl; each Re is independently H, halo, —CN, —NRcRc, —OH, —C1-6alkyl, —OC1-6alkyl or a 5 to 6 membered heterocycloalkyl group having from 1 to 3 heteroatoms independently selected from O, N or S; each n is independently 0, 1, 2, 3 or 4; each m is independently 0, 1, 2, 3 or 4.
地址 Thousand Oaks CA US